The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Regulatory News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

26 Jun 2018 10:15

RNS Number : 5986S
Reckitt Benckiser Group PLC
26 June 2018
 

Dr. Mehmood Khan to join RB Board, strengthening further its scientific and sustainability focus

 

June 26, 2018, Slough UK -Today RB is pleased to announce the appointment of Dr. Mehmood Khan to the Board, with effect from July 1st 2018.

Dr. Khan is the Vice Chairman and Chief Scientific Officer, Global Research and Development, at PepsiCo, the global food and beverage company with net revenues of over $63 billion.

In his role, Dr. Khan oversees the PepsiCo global Performance with Purpose sustainability initiatives, inspired by the belief that business success is inextricably linked to the sustainability of the world. Dr. Khan also leads PepsiCo's R&D efforts, creating breakthrough innovations in food, beverages and nutrition.

Prior to joining PepsiCo, Dr. Khan was President, Takeda Global Research & Development Center, overseeing Takeda Pharmaceuticals Company's worldwide R&D efforts. Previously, Dr. Khan was a faculty member at the Mayo Clinic and Mayo Medical School in Rochester, Minnesota, serving as Director of the Diabetes, Endocrine and Nutritional Trials Unit in the endocrinology division. He earned his medical degree from the University of Liverpool Medical School and is a Fellow of the Royal College of Physicians, London.

Dr. Khan is also an independent director of biopharmaceutical company CorMedix.

Commenting on the appointment, Chris Sinclair, Chairman of the Board of RB, said "I am delighted that Mehmood has agreed to join the Board. He brings enormous experience as a medical practitioner and researcher, and in the application of science to the development of consumer products, in particular in the field of nutrition. He is also a seasoned executive on the management team of a global consumer products company, with extensive experience in both developing and developed markets. I am confident that he will make a significant contribution to RB and the Board."

Dr. Khan will also join RB's Corporate Responsibility, Sustainability, Ethics and Compliance Committee which is chaired by Pam Kirby.

The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to Dr. Khan's appointment.

 

For further information, please contact:

Reckitt Benckiser +44 (0)1753 217800

Patty O'Hayer

Finsbury +44 (0)207 251 3801

Catherine Boyle

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

About RB

RB is the global leading consumer health, hygiene and home company. Driven by a purpose to build healthier lives and happier homes, RB has operations in over 60 countries. From the foundations of wellness and infant nutrition, to the fundamentals of a hygienic home, our global brands help people live healthier, happier lives.

RB has world leading Powerbrands which include household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.

RB's unique culture is at the heart of its success. Its drive to achieve, passion to outperform and commitment to quality and scientific excellence are manifested in the work of over 40,000 RB employees worldwide.

For more information visit www.rb.com 

 

*RB is the trading name of the Reckitt Benckiser group of companies

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUGGQUPRUBQ
Date   Source Headline
9th Apr 202010:00 amRNSDirectorate Change
6th Apr 202011:42 amRNSAnnual Financial Report
3rd Apr 202010:31 amRNSDirector Declaration
1st Apr 202011:26 amRNSTotal Voting Rights
24th Mar 20204:57 pmRNSDirector/PDMR Shareholding
24th Mar 20204:41 pmRNSSecond Price Monitoring Extn
24th Mar 20204:35 pmRNSPrice Monitoring Extension
12th Mar 20205:08 pmRNSDirector/PDMR Shareholding
9th Mar 20204:45 pmRNSDirector/PDMR Shareholding
3rd Mar 20204:26 pmRNSDirector/PDMR Shareholding
2nd Mar 20201:11 pmRNSTotal Voting Rights
27th Feb 20207:00 amRNSFull Year Results 2019
3rd Feb 202011:16 amRNSTotal Voting Rights
2nd Jan 202012:20 pmRNSTotal Voting Rights
4th Dec 20191:30 pmRNSDirectorate Change
2nd Dec 201912:00 pmRNSTotal Voting Rights
1st Nov 201912:00 pmRNSTotal Voting Rights
29th Oct 20194:30 pmRNSDirector/PDMR Shareholding
28th Oct 201911:21 amRNSDirector/PDMR Shareholding
24th Oct 20192:30 pmRNSDirector/PDMR Shareholding
22nd Oct 20197:00 amRNSQ3 2019 Trading Update
21st Oct 201910:15 amRNSDirectorate Change
1st Oct 201911:51 amRNSTotal Voting Rights
30th Sep 20193:12 pmRNSDirector/PDMR Shareholding
18th Sep 201912:00 pmRNSDirectorate Change
3rd Sep 20191:00 pmRNSDirector/PDMR Shareholding
2nd Sep 20191:00 pmRNSDirectorate Change
2nd Sep 201912:37 pmRNSTotal Voting Rights
30th Aug 20193:00 pmRNSDirector/PDMR Shareholding
6th Aug 20192:07 pmRNSDirector/PDMR Shareholding
1st Aug 20199:48 amRNSTotal Voting Rights
30th Jul 20197:00 amRNSHalf Year Results 2019
29th Jul 20199:30 amRNSDirectorate Change
11th Jul 20197:00 amRNSAgreement to resolve all federal investigations
1st Jul 201911:31 amRNSTotal Voting Rights
12th Jun 20197:00 amRNSRB CEO Announcement
3rd Jun 201910:49 amRNSTotal Voting Rights
28th May 201910:40 amRNSDirector/PDMR Shareholding
23rd May 20194:40 pmRNSDirector/PDMR Shareholding
22nd May 201911:45 amRNSDirector/PDMR Shareholding
13th May 20193:01 pmRNSDirector/PDMR Shareholding
9th May 20193:28 pmRNSResult of AGM
2nd May 20197:00 amRNSQ1 Trading Update
1st May 201910:46 amRNSDirectorate Change
1st May 20199:00 amRNSTotal Voting Rights
10th Apr 201910:37 amRNSUS Justice Department indictment of Indivior Plc
4th Apr 201912:45 pmRNSDirector Declaration
2nd Apr 20194:56 pmRNSAnnual Financial Report
1st Apr 20199:30 amRNSTotal Voting Rights
27th Mar 20192:58 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.